Northern Trust Corp Buys 39,289 Shares of Certara, Inc. $CERT

Key Points

• Northern Trust Corp increased its holdings in Certara, Inc. by 4.5%, owning approximately 0.56% of the company valued at $9,071,000 as of the last SEC filing.
• Certara reported quarterly earnings of $0.07 per share, missing estimates, but revenue of $104.57 million exceeded expectations, marking a 12.1% increase year-over-year.
• Wall Street analysts have mixed ratings on Certara, with a consensus price target of $15.14 and five analysts rating it as a "Buy".

Northern Trust Corp grew its stake in Certara, Inc. (NASDAQ:CERT - Free Report) by 4.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 916,299 shares of the company's stock after purchasing an additional 39,289 shares during the period. Northern Trust Corp owned about 0.56% of Certara worth $9,071,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Geneva Capital Management LLC boosted its stake in shares of Certara by 3.9% in the 1st quarter. Geneva Capital Management LLC now owns 5,671,689 shares of the company's stock valued at $56,150,000 after purchasing an additional 213,089 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Certara by 864.0% in the 4th quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company's stock valued at $40,253,000 after purchasing an additional 3,387,590 shares in the last quarter. Mackenzie Financial Corp boosted its stake in shares of Certara by 7.0% in the 1st quarter. Mackenzie Financial Corp now owns 1,793,327 shares of the company's stock valued at $17,754,000 after purchasing an additional 117,089 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Certara by 5.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 797,610 shares of the company's stock valued at $7,896,000 after purchasing an additional 40,218 shares in the last quarter. Finally, Kopion Asset Management LLC boosted its stake in shares of Certara by 8.0% in the 1st quarter. Kopion Asset Management LLC now owns 600,159 shares of the company's stock valued at $5,942,000 after purchasing an additional 44,516 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Trading Up 1.7%

Certara stock traded up $0.18 during mid-day trading on Monday, hitting $10.70. 1,622,894 shares of the stock were exchanged, compared to its average volume of 1,126,466. The company has a quick ratio of 2.16, a current ratio of 2.16 and a debt-to-equity ratio of 0.27. Certara, Inc. has a 12 month low of $8.64 and a 12 month high of $15.69. The firm's fifty day simple moving average is $10.78 and its two-hundred day simple moving average is $11.31. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of 214.04 and a beta of 1.43.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a return on equity of 5.11% and a net margin of 1.97%.The firm had revenue of $104.57 million for the quarter, compared to the consensus estimate of $104.14 million. During the same quarter in the previous year, the business posted $0.07 EPS. The firm's revenue for the quarter was up 12.1% compared to the same quarter last year. Analysts forecast that Certara, Inc. will post 0.28 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. UBS Group cut their target price on shares of Certara from $17.50 to $15.00 and set a "buy" rating on the stock in a research report on Thursday, August 7th. Morgan Stanley assumed coverage on shares of Certara in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 target price on the stock. Finally, KeyCorp cut their target price on shares of Certara from $18.00 to $15.00 and set an "overweight" rating on the stock in a research report on Monday, July 14th. Five analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $15.14.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.